Turnstone Biologics (NASDAQ:TSBX) Price Target Lowered to $3.75 at Piper Sandler

Turnstone Biologics (NASDAQ:TSBX) had its price objective lowered by Piper Sandler from $20.00 to $3.75 in a research report report published on Monday, Benzinga reports. Piper Sandler currently has an overweight rating on the stock.

Separately, Bank of America decreased their target price on Turnstone Biologics from $12.00 to $10.00 and set a buy rating on the stock in a report on Monday.

Turnstone Biologics Price Performance

NASDAQ:TSBX opened at $0.79 on Monday. The firm has a market cap of $18.30 million and a PE ratio of -0.08. Turnstone Biologics has a 12 month low of $0.73 and a 12 month high of $12.16. The company’s 50-day moving average price is $2.32 and its two-hundred day moving average price is $2.74.

Turnstone Biologics (NASDAQ:TSBX) last announced its earnings results on Wednesday, August 14th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.08). On average, research analysts expect that Turnstone Biologics will post -3.44 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Zimmer Partners LP boosted its position in Turnstone Biologics by 271.4% in the 1st quarter. Zimmer Partners LP now owns 179,026 shares of the company’s stock valued at $469,000 after buying an additional 130,826 shares during the last quarter. Kathleen S. Wright Associates Inc. acquired a new position in shares of Turnstone Biologics during the first quarter valued at $111,000. Finally, Sei Investments Co. acquired a new position in shares of Turnstone Biologics during the second quarter valued at $31,000. Institutional investors own 52.51% of the company’s stock.

Turnstone Biologics Company Profile

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas.